FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1010-1011 October 12, 1995 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Taplin, M.-E. PubMed Citation

To the Editor: The study by Taplin and colleagues (May 25 issue)¹ provides strong evidence supporting the role of mutant androgen receptors in the emergence of prostate cancer refractory to hormone treatment. We were surprised, however, that these investigators tested the function of the mutated androgen receptors only with estradiol and progesterone. Although stimulation of mutant androgen receptors by these steroids may prove to be of clinical importance, we think that possible functional effects of antiandrogens (such as hydroxyflutamide and bicalutamide) and weak adrenal androgens (such as androstenedione and dehydroepiandrosterone) on mutated androgen receptors are more relevant.

We have hypothesized . . . [Full Text of this Article]

References

This article has been cited by other articles:

• WALLEY, T., DUNDAR, Y., HILL, R., DICKSON, R. (2003). Superiority and equivalence in thrombolytic drugs: an interpretation. QJM 96: 155-160 [Full Text]